CRISPR and Beyond with Vertex CSO David Altshuler, MD, PhD—ASGCT's The Issue

Join host Emily Walsh Martin, PhD, and David Altshuler, MD, PhD, Chief Scientific Officer of Vertex Pharmaceuticals. David came to Vertex after a lengthy career in medicine and academic research. David and Emily discuss how David and the team at Vertex think about innovation in drug development and how that impacts how they select programs and approaches for the diseases they focus on. They also cover what he’d love to see happen with new cell and gene platform technologies being brought forward. Now is the time to register for the ASGCT Policy Summit, held in Washington DC on September 23-24. Whether you attend in person or virtually, you will not want to miss this year’s program. Great sessions are planned on reimbursement, Medicaid, venture capital, strategic investment outlooks, and the evolution of the regulatory landscape. Advanced registration ends August 23, so register today! ASGCT.org/PolicySummit Music by: https://www.steven-obrien.net/--------------------------Bright New Morning - Steven O'Brien (Used for free under a Creative Commons Attribution 4.0 License: https://creativecommons.org/licenses/by/4.0/)Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.